Consultant analyzing a mammogram
Media playback is unsupported on your device

Breast cancer drug Kadcyla price reduction urged

The medicines watchdog for England and Wales says it is disappointed that the drug company Roche will not reduce the price of a new breast cancer drug for the NHS.

NICE says the drug, Kadcyla, is too expensive at more than £90,000 a year per patient. The drug can add months to the life of women dying of breast cancer.

Dominic Hughes reports.

  • 23 Apr 2014
Go to next video: GP questions breast cancer self checks